Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $35.50 Average PT from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $35.57.

A number of brokerages recently commented on CAPR. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Oppenheimer cut their price target on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating for the company in a report on Monday. Jones Trading cut their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Tuesday. Finally, Roth Capital reissued a “buy” rating and issued a $31.00 price target on shares of Capricor Therapeutics in a report on Tuesday, June 17th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock worth $1,536,000 after acquiring an additional 37,868 shares during the last quarter. Swiss National Bank bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth $930,000. Nuveen Asset Management LLC lifted its holdings in shares of Capricor Therapeutics by 392.7% during the 4th quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company’s stock worth $2,334,000 after acquiring an additional 134,791 shares during the last quarter. Alliancebernstein L.P. bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth $183,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Capricor Therapeutics by 22.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 2,361 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Capricor Therapeutics Trading Up 8.6%

Shares of CAPR stock opened at $10.05 on Thursday. The stock has a market capitalization of $459.08 million, a P/E ratio of -7.08 and a beta of 0.84. The firm’s 50 day moving average is $10.91 and its 200 day moving average is $12.42. Capricor Therapeutics has a 12 month low of $3.52 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. During the same quarter in the previous year, the company posted ($0.31) earnings per share. On average, equities analysts predict that Capricor Therapeutics will post -1.21 EPS for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.